{"id":"ketonaph","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Corneal effects (including keratitis)"},{"rate":null,"effect":"Stinging or burning upon instillation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"KetoNaph works by blocking COX-1 and COX-2 enzymes in ocular tissues, thereby reducing the production of prostaglandins that mediate inflammation, pain, and other inflammatory responses. As a topical ophthalmic formulation, it delivers the active ingredient directly to the eye to manage postoperative inflammation and pain following cataract surgery and other ocular procedures.","oneSentence":"KetoNaph is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:51.122Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postoperative inflammation and pain following cataract surgery"},{"name":"Postoperative inflammation and pain following refractive surgery"}]},"trialDetails":[{"nctId":"NCT00769886","phase":"PHASE3","title":"Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-10","conditions":"Allergic Conjunctivitis","enrollment":144},{"nctId":"NCT00770133","phase":"PHASE3","title":"Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-02","conditions":"Allergic Conjunctivitis","enrollment":141},{"nctId":"NCT01159015","phase":"PHASE3","title":"Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-07","conditions":"Allergic Conjunctivitis","enrollment":534}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"KetoNaph","genericName":"KetoNaph","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KetoNaph is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain in the eye. Used for Postoperative inflammation and pain following cataract surgery, Postoperative inflammation and pain following refractive surgery.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}